Home » What » Recent Articles:

What Does IMS Health Do, Anyway?

November 7, 2009 Doctors No Comments

By Jacob Goldstein

What Does IMS Health Do, Anyway?IMS Health is nearing a deal to sell itself for nearly $4 billion, the WSJ reports. That raises a simple question: What does IMS Health do, anyway?

Drug companies pay IMS for information about the prescribing habits of individual doctors. This, of course, is very valuable stuff for the drug company sales reps who make calls at doctors’ offices. IMS buys the raw prescription data — which doesn’t … Continue Reading

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009 Cancer, Drugs, Research No Comments

By Jonathan D. Rockoff

What Will Pfizer’s R&D Look Like a Year from Now?Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael Dolsten, a former Wyeth executive who will oversee vaccines and biotech drugs.

Following a popular trend in the … Continue Reading

What the Health Care Bills Do (and Don’t Do) for Primary Care

October 13, 2009 Doctors, Medicare No Comments

By Jacob Goldstein

What the Health Care Bills Do (and Don’t Do) for Primary CareYes, the big health-care bills moving through Congress include a few measures to increase the number of primary-care doctors. No, those measures probably aren’t enough to satisfy the demand for primary-care projected by medical educators and others, Kaiser Health News reports

Medicare payments to primary-care docs would be boosted by 10% under the the House and Senate bills. And about 1,000 residency … Continue Reading

Partner links

Advertising

Drugs

South Korean FDA Probes Roche for Aiding Tamiflu Stockpiling

November 8, 2009

By Shirley S. Wang Should companies be allowed to buy large quantities of medicine like Tamiflu to have on hand in case their employees develop the H1N1 flu virus? Not according to the law in South Korea, where it’s illegal for non-medical professionals to purchase big lots of drugs. Punishment is up to five years [...]

Boosting Medical Students’ Training in Drug Abuse

November 7, 2009

By Shirley S. Wang There’s lot of action these days aimed at curbing the abuse of prescription drugs. The FDA is working on a plan to make it harder for people to get access to unauthorized prescription painkillers, pain specialists have come out with guidelines to help doctors manage pain-drug-abusing patients and drug companies have [...]

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael [...]

See Your Doctor: The Dawn of Consumer Drug Ads

October 13, 2009

By Jacob Goldstein For a look back at a key breakthrough in the history of the pharmaceutical industry, we turn now to Joe Davis, a retired ad guy who lives in Vermont. Back in the mid-1980s, Davis came up with an idea: Run a TV ad for Seldane, the allergy medicine, but don’t say the [...]

Why Other Drugmakers Want to Be More Like J&J

October 12, 2009

By Jacob Goldstein Johnson & Johnson’s third-quarter earnings, out today, provide the latest reminder of why other drugmakers want to be more like J&J. In a nutshell: It’s a tough time to be in the prescription drug business, what with stiff competition from generics manufacturers and payers pushing for lower costs on branded drugs. So [...]

Related Links

Research

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael [...]

Are Mammograms and PSA Tests Overrated?

October 21, 2009

By Jacob Goldstein Catch cancers early and treat them before they become deadly. That’s the idea behind cancer screening, and that’s clearly how it works with pap smears for cervical cancer and colonoscopy for colon cancer. But in some cases screening can lead to aggressive treatment of slow-growing tumors that would never have caused a [...]

The Problem With Ranking Countries’ Health-Care Systems

October 20, 2009

By Jacob Goldstein The oft-cited WHO ranking that said the U.S. has the 37th best health-care system in the world is dated and had problems even when it was new, WSJ stats maven Carl Bialik writes in his column today. The ranking was published in 2000, and came up against a major problem: Good data [...]